Table 2. Impact of statin use on adjusted primary endpoints and secondary endpoints.
| Outcome | No statin group (n=2,869) | Statin group (n=768) | Adjusted hazard ratio | P value |
|---|---|---|---|---|
| 30 day | ||||
| Death | 61/2,869 | 5/768 | 0.358 (0.1-0.7) | 0.007 |
| 1 year | ||||
| Stroke | 14/2,869 | 4/768 | 0.92 (0.3-3.4) | 0.87 |
| MI | 8/2,869 | 4/768 | 1.92 (0.3-4.9) | 0.708 |
| Death | 165/2,869 | 19/768 | 2.23 (1.6-2.6) | 0.005 |
| Death/MI/stroke | 187/2,869 | 27/768 | 1.85 (1.4-1.9) | 0.005 |
| Overall | ||||
| Stroke | 97/2,869 | 22/768 | 1.2 (0.5-1.4) | 0.518 |
| Death | 533/2,869 | 96/768 | 1.5 (1.2-1.7) | 0.032 |
| MI | 58/2,869 | 17/768 | 0.91 (0.6-2.1) | 0.588 |
| Death/MI/stroke | 688/2,869 | 135/768 | 1.4 (1.2-1.6) | 0.052 |
Adjusted for age, sex, ejection fraction, medications atrial fibrillation. MI, myocardial infarction.